PROQR THERAPEUTICS NV (PRQR)

Company Profile

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 130 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Company Info

PROQR THERAPEUTICS NV

Zernikedreef 9

Leiden ZUID-HOLLAND 2333 CK

P: 31881667000

CEO: Daniel de Boer

Employees: 130

Website: https://www.proqr.com/